WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Wayne Bennett, at 74, signs a 3
Quentin Tarantino SCRAPS plans for his final film The Movie Critic which had Brad Pitt set to star
As Kansas City Chiefs star Patrick Mahomes insists his 'dad bod' is 'great' for his NFL performance
Paris Olympics opening ceremony on river Seine will last nearly 4 hours
Iran's nuclear policy unlikely to change even after president's death
Gunman shot himself and wasn't killed by officer, chief says
Kate Beckinsale sheds light on her recent health woes as she wears 'tummy troubles survivor' T
Civilian interrogator defends work at Abu Ghraib, tells jury he was promoted
Congo names third American in a foiled coup plot as mourners gather in Utah to remember plot leader
Tesla shares tumble below $150 per share, giving up all gains made over the past year
Kansas takes control in the ninth and beats Kansas State in the opener of the Big 12 Tournament
Gunmen ambush vehicle carrying customs officials in northwest Pakistan, killing 4 officers